Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 12/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | USP1 | O94782 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19430087 | 0.90 | AOC3 (0.42) | AOC3PRMT6MTOR | |
| SCHEMBL19429824 | 0.88 | AOC3 (0.43) | AOC3PRMT6MTOR | |
| SCHEMBL19430397 | 0.86 | AOC3 (0.48) | AOC3PRMT6 | |
| SCHEMBL19430062 | 0.85 | AOC3 (0.40) | AOC3PRMT6MTOR | |
| SCHEMBL19430304 | 0.84 | SCD5 (0.39) | AOC3TRPV3 | |
| SCHEMBL19429906 | 0.83 | AOC3 (0.41) | AOC3PRMT6MTOR | |
| SCHEMBL19430181 | 0.83 | AOC3 (0.38) | AOC3PRMT6 | |
| SCHEMBL19430078 | 0.83 | AOC3 (0.38) | AOC3USP1TRPV3 | |
| SCHEMBL19429870 | 0.83 | AOC3 (0.39) | AOC3TRPV3 | |
| SCHEMBL19429839 | 0.83 | AOC3 (0.39) | AOC3PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | AOC3 2654/4885PRMT6 4/4885MTOR 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.